Adenoviral Delivery of Pan-Caspase Inhibitor P35 Enhances Bystander Killing by P450 Gene-Directed Enzyme Prodrug Therapy Using Cyclophosphamide Report as inadecuate


Adenoviral Delivery of Pan-Caspase Inhibitor P35 Enhances Bystander Killing by P450 Gene-Directed Enzyme Prodrug Therapy Using Cyclophosphamide


Adenoviral Delivery of Pan-Caspase Inhibitor P35 Enhances Bystander Killing by P450 Gene-Directed Enzyme Prodrug Therapy Using Cyclophosphamide - Download this document for free, or read online. Document in PDF available to download.

Citation

Doloff, Joshua C, Ting Su, David J Waxman. -Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+- BMC Cancer 10:487. 2010

Abstract

BACKGROUND. Cytochrome P450-based suicide gene therapy for cancer using prodrugs such as cyclophosphamide CPA increases anti-tumor activity, both directly and via a bystander killing mechanism. Bystander cell killing is essential for the clinical success of this treatment strategy, given the difficulty of achieving 100% efficient gene delivery in vivo using current technologies. Previous studies have shown that the pan-caspase inhibitor p35 significantly increases CPA-induced bystander killing by tumor cells that stably express P450 enzyme CYP2B6 Schwartz et al, 2002 Cancer Res. 62: 6928-37. METHODS. To further develop this approach, we constructed and characterized a replication-defective adenovirus, Adeno-2B6-p35, which expresses p35 in combination with CYP2B6 and its electron transfer partner, P450 reductase. RESULTS. The expression of p35 in Adeno-2B6-p35-infected tumor cells inhibited caspase activation, delaying the death of the CYP2B6 -factory- cells that produce active CPA metabolites, and increased bystander tumor cell killing compared to that achieved in the absence of p35. Tumor cells infected with Adeno-2B6-p35 were readily killed by cisplatin and doxorubicin, indicating that p35 expression is not associated with acquisition of general drug resistance. Finally, p35 did not inhibit viral release when the replication-competent adenovirus ONYX-017 was used as a helper virus to facilitate co-replication and spread of Adeno-2B6-p35 and further increase CPA-induced bystander cell killing. CONCLUSIONS. The introduction of p35 into gene therapeutic regimens constitutes an effective approach to increase bystander killing by cytochrome P450 gene therapy. This strategy may also be used to enhance other bystander cytotoxic therapies, including those involving the production of tumor cell toxic protein products.Rights

Copyright 2010 Doloff et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http:-creativecommons.org-licenses-by-2.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CAS: Biology: Scholarly Papers -



Author: Doloff, Joshua C. - Su, Ting - Waxman, David J. - -

Source: https://open.bu.edu/







Related documents